1. PET and radionuclides in prostate cancer
   María Nieves Cabrera-Martín et al, 2024, Revisiones en Cáncer CrossRef
2. The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer
   Ruohua Chen et al, 2022, Journal of Nuclear Medicine CrossRef
3. Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia
   Yiping Shi et al, 2021, Frontiers in Oncology CrossRef
4. Combination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer
   F. Kepenek et al, 2023, Médecine Nucléaire CrossRef
5. 18F-FDG PET Is Not Inferior to 68Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study
   Lian Xu et al, 2023, Diagnostics CrossRef
6. Liquid Biopsy in Oligometastatic Prostate Cancer—A Biologist's Point of View
   Ewelina Stelcer et al, 2019, Frontiers in Oncology CrossRef
7. Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT
   Ruohua Chen et al, 2021, European Journal of Nuclear Medicine and Molecular Imaging CrossRef
8. The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis
   Kun Liu et al, 2017, Oncotarget CrossRef
9. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer
   Hossein Jadvar, 2016, Journal of Nuclear Medicine CrossRef
10. Male Pelvis on FDG PET/CT
    Gary A. Ulaner, 2019, Fundamentals of Oncologic PET/CT CrossRef
11. Multimodal Imaging-Based Potential Visualization of the Tumor Microenvironment in Bone Metastasis
    Jang Bae Moon et al, 2021, Cells CrossRef
12. Molecular Imaging of Prostate Cancer
    Moozhan Nikpanah et al, 2020, Prostate MRI Essentials CrossRef
13. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment
    Hossein Jadvar et al, 2020, Journal of Nuclear Medicine CrossRef
14. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma
    Kalevi Kairemo et al, 2017, Diagnostics CrossRef
15. PET/MRI in Prostate Cancer
    Ida Sonni et al, 2018, PET/MRI in Oncology CrossRef
16. Is There Use for FDG-PET in Prostate Cancer?
    Hossein Jadvar, 2016, Seminars in Nuclear Medicine CrossRef
17. Association betweenHIF1Ars11549465 polymorphism and risk of prostate cancer: a meta-analysis
    Xiao-Dong Li et al, 2017, Oncotarget CrossRef
18. Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment
    Junbao Wei et al, 2018, Oncotarget CrossRef